바이오정보모아 (BioJungboMoa) — ADC · Antibody · CGT 임상·약리 비교

8428프로그램 40FDA 승인

225오늘 방문

4,859누적 방문

7303갱신 대기 S–CData Tier S/A/B차세대 →Insight 1032HER2 breast 4683Antibody 2713CGT →Psoriasis →NSCLC 40FDA 승인

피드 Data Tier 차세대 Insight

추천 비교

비교 도구 →

HER2 ADCEnhertu · Kadcyla · RC48 CD19 CAR-TYescarta · Kymriah PD-1Keytruda · Opdivo 다발골수종Darzalex · Blenrep TROP2 ADCTrodelvy · Dato-DXd · SG Nectin-4 · TROP2Padcev · Trodelvy 건선 IL pathwayStelara · Cosentyx · Skyrizi Anti-VEGF (안과)Eylea · Lucentis Anti-TNFHumira · Enbrel IL-12/23Stelara · Skyrizi 아토피·IL-13Dupixent · Ebglyss PCSK9 · LDLRepatha · Praluent · Leqvio GLP-1 · incretinSemaglutide · Tirzepatide 혈우병 유전자치료Hemgenix · Roctavian 겸상적혈구 CGTCasgevy · Lyfgenia 망막·DMD 유전자치료Luxturna · Elevidys

CGTABiologicstaleAstraZenecaPhase 2

autologous CD19-directed chimeric antigen receptor (CAR, autologous CD19-directed chimeric antigen receptor, autologous CD19-directed chimeric antigen receptor (CAR) T-cells)

Relapsed Non Hodgkin Lymphoma; Relapsed Adult ALL · CD19

#CD19#CGT#Phase2#인기#세포유전치료+5

효능 ORR 77.3%임상시험 96상태 RECRUITING

AntibodyBstaleNovartisPhase 3

secukinumab (AIN457, AIN457 (secukinumab))

Asthma · Psoriatic Arthritis

#PsoriaticArthritis#Antibody#Phase3#인기#항체+4

효능 ORR 53%임상시험 95상태 ACTIVE

ADCBBiologicstaleGileadPhase 2

SG (Sacituzumab Govitecan-hziy, Sacituzumab Govitecan-hziy (SG))

Lung Cancer; Advanced or Metastatic Non-Small-Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#ADC#Phase2#인기#항체약물접합체+4

효능 ORR 34.3%임상시험 94상태 RECRUITING

AntibodyCstaleJunshi Biosciencesvedotin (EV) in combination…Phase 3

Toripalimab (Toripalimab)

Metastatic Colorectal Cancer; Liver Metastases · Gastric Cancer

#GastricCancer#Antibody#Phase3#인기#항체+5

임상시험 93상태 RECRUITING

ADCABiologicstaleAstraZenecaPhase 2

5-FU (Fluorouracil, Fluorouracil (5-FU))

Gastric Cancer · Gastric Cancer

#GastricCancer#ADC#Phase2#인기#항체약물접합체+2

효능 ORR 63.5%임상시험 93상태 RECRUITING

ADCABiologicstaleAmgenPhase 3

Pegfilgrastim (Pegfilgrastim)

Cancer; Colon Cancer · Ovarian Cancer

#OvarianCancer#ADC#Phase3#인기#항체약물접합체+4

효능 ORR 56.7%임상시험 93상태 RECRUITING

ADCBBiologicstaleJiangsu Simcere Pharmaceutical …Phase 3

Palbociclib (Palbociclib)

Head and Neck Squamous Cell Carcinoma · FRα

#FR#ADC#Phase3#인기#항체약물접합체+3

효능 ORR 79.5%임상시험 92상태 DISCONTINUED

AntibodySHOTFDACuratedFDABiologicAbbVieApproved

risankizumab (Skyrizi)

Psoriasis, psoriatic arthritis, Crohn's disease · IL-23 (p19)

#IL-23p19#Antibody#Approved#FDA승인#바이오정보모아추천+5

효능 ORR 90%임상시험 91상태 APPROVED

ADCABiologicstaleDaiichi Sankyoderuxtecan (Dato-DXd, Datro…Phase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Trastuzumab Deruxtecan (T-DXd) monotherapy)

Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma · Gastric Adenocarcinoma

#GastricAdenocarcinoma#ADC#Phase2#인기#항체약물접합체+5

효능 ORR 79.7%임상시험 91상태 RECRUITING

ADCBBiologicstaleBayerPhase 3

Regorafenib (Regorafenib)

Metastatic Colorectal Cancer · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#ADC#Phase3#인기#항체약물접합체+3

효능 ORR 54%임상시험 90상태 RECRUITING

AntibodyAstaleRochePhase 3

atezolizumab (Tecentriq, MPDL3280A, Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody)

Triple-Negative Breast Cancer · Colorectal Cancer

#ColorectalCancer#Antibody#Phase3#인기#항체+4

효능 ORR 76.7%임상시험 90상태 ACTIVE

ADCCBiologicstaleCelgenePhase 2

5-Azacytidine (5-Azacytidine)

Leukemia · Leukemia

#Leukemia#ADC#Phase2#인기#항체약물접합체+2

효능 ORR 75%임상시험 89상태 DISCONTINUED

ADCCBiologicstaleAcademic and Community Cancer R…Phase 2

Cabozantinib (Cabozantinib)

Locally Advanced Hepatocellular Carcinoma; Metastatic Hepatocellular Carcinoma · FRα

#FR#ADC#Phase2#인기#항체약물접합체+5

효능 ORR 59%임상시험 89상태 DISCONTINUED

AntibodySHOTFDACuratedFDABiologicAmgenApproved

evolocumab (Repatha, AMG-145)

Hyperlipidemia, ASCVD risk reduction, HeFH, HoFH · PCSK9

#PCSK9#Antibody#Approved#FDA승인#바이오정보모아추천+5

효능 LDL-C ↓59%임상시험 88상태 APPROVED

AntibodyAstaleRochePhase 3

atezolizumab (Tecentriq, MPDL3280A, Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody)

Carcinoma, Non-Squamous Non-Small Cell Lung · PD-L1

#PD-L1#Antibody#Phase3#인기#항체+5

효능 ORR 76.7%임상시험 88상태 ACTIVE

ADCBBiologicstaleDaiichi Sankyoderuxtecan, sacituzumab gov…Phase 2

Up-Titration (Patritumab Deruxtecan, Patritumab Deruxtecan (Up-Titration))

Non-Small Cell Lung Cancer Metastatic; Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor · Non-Small Cell Lung Cancer Metastatic

#Non-SmallCellLungCancerMetastati#ADC#Phase2#인기#항체약물접합체+5

효능 ORR 64%임상시험 88상태 RECRUITING

ADCBBiologicstaleDaiichi SankyoPhase 2

Fixed dose (Patritumab Deruxtecan, Patritumab Deruxtecan (Fixed dose))

Non-Small Cell Lung Cancer Metastatic; Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor · Non-Small Cell Lung Cancer Metastatic

#Non-SmallCellLungCancerMetastati#ADC#Phase2#인기#항체약물접합체+4

효능 ORR 64%임상시험 88상태 RECRUITING

AntibodyCstaleJanssenPhase 2

Tec (Teclistamab, Teclistamab (Tec))

AL Amyloidosis · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase2#인기#항체+4

임상시험 88상태 RECRUITING

ADCCBiologicstaleAlliance for Clinical Trials in…Phase 2

Dasatinib (Dasatinib)

Glioblastoma Multiforme · FRα

#FR#ADC#Phase2#인기#항체약물접합체+3

효능 ORR 27%임상시험 87상태 DISCONTINUED

ADCBBiologicstaleGileadaxisPhase 3

sacituzumab govitecan (Trodelvy)

Breast Cancer; Metastatic Breast Cancer · Locally Advanced or Metastatic Urothelia

#LocallyAdvancedorMetastaticUroth#ADC#Phase3#인기#항체약물접합체+5

효능 ORR 44%임상시험 87상태 RECRUITING

AntibodyBstaleEli Lilly and CompanyDeruxtecan]Phase 3

Ramucirumab (Ramucirumab)

Advanced Esophageal Adenocarcinoma; Advanced Gastric Adenocarcinoma · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase3#인기#항체+5

효능 ORR 40%임상시험 86상태 RECRUITING

ADCSFDAFDABiologicAstellasvedotin plus pembrolizumab …Approved

enfortumab vedotin (Padcev)

Metastatic Bladder Urothelial Carcinoma; Metastatic Renal Pelvis and Ureter Urothelial Carcinoma · Renal Pelvis and Ureter Urothelial Carci

#RenalPelvisandUreterUrothelialCa#ADC#Approved#FDA승인#인기+5

효능 ORR 44%임상시험 84상태 RECRUITING

AntibodyCstaleRegeneronPhase 2

Cemiplimab (Cemiplimab)

Breast Neoplasms; Breast Cancer · Solid Tumor

#SolidTumor#Antibody#Phase2#인기#항체+5

효능 ORR 44%임상시험 84상태 RECRUITING

ADCABiologicstaleDaiichi Sankyoderuxtecan (Dato-DXd, Datro…Phase 2

T-DXd, DS-8201a (Trastuzumab deruxtecan, Trastuzumab deruxtecan (T-DXd, DS-8201a))

Advanced Breast Cancer; Advanced Breast Carcinoma · Advanced Breast Cancer

#AdvancedBreastCancer#ADC#Phase2#인기#항체약물접합체+5

효능 ORR 79.7%임상시험 84상태 RECRUITING

ADCSBiologicstaleDaiichi Sankyoderuxtecan (Dato-DXd, Datro…Phase 3

DS-8201a (Trastuzumab deruxtecan, Trastuzumab deruxtecan (DS-8201a))

Breast Cancer; Non-small Cell Lung Carcinoma · Breast Cancer

#BreastCancer#ADC#Phase3#인기#항체약물접합체+5

효능 ORR 79.7%임상시험 84상태 RECRUITING

4 / 142 페이지

← 이전 다음 →

전체 8,428개 프로그램 보기